Enliven Therapeutics Upsizes Public Offering to $400M+ to Fund Lead Drug Development
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (4.8× avg).
Summary
Enliven Therapeutics finalized an upsized public offering, raising approximately $400 million to fund the advancement of its lead drug candidate, ELVN-001, into Phase 3 trials and extend its cash runway into 2030.
Key Events · Financing and Capital Events · ELVN
-
Offering Finalized and Upsized
Enliven Therapeutics finalized its public offering, raising approximately $400 million (or $460 million if the underwriters' option is fully exercised) through the sale of 8,933,334 shares of common stock and pre-funded warrants to purchase 1,733,333 shares. This represents an upsize from the initially proposed $250 million offering.
-
Pricing Details
The offering was priced at $37.50 per share for common stock and $37.499 per pre-funded warrant (with a nominal $0.001 exercise price). This was a slight premium to the last reported sale price of $37.00 on June 10, 2026, before the offering was announced.
-
Significant Dilution
The offering involves the issuance of 10,666,667 shares (common stock and shares underlying warrants), potentially increasing to 12,266,667 shares if the underwriters' option is fully exercised. This represents a potential dilution of over 20% to existing shareholders based on shares outstanding as of March 31, 2026.
-
Funding for Lead Drug Candidate ELVN-001
The net proceeds, estimated at $376.0 million (or $432.4 million with option exercise), will primarily fund ongoing research and development activities, including the advancement of ELVN-001 in ongoing and planned clinical trials across multiple lines of therapy, and initial commercial readiness activities.
Analysis · ELVN · Life Sciences
Enliven Therapeutics has finalized and upsized its public offering, raising approximately $400 million (potentially $460 million if the underwriters' option is fully exercised) through the sale of common stock and pre-funded warrants. This significant capital infusion, representing over 15% of the company's market capitalization, is crucial for funding the advancement of its lead drug candidate, ELVN-001, into planned Phase 3 clinical trials. The offering was priced at $37.50 per share, a slight premium to the last reported sale price of $37.00 on June 10, 2026, before the offering was announced, but a discount to today's market price of $45.47. This capital raise extends the company's cash runway into 2030, providing essential resources following recent positive Phase 1 data and FDA agreement for the ELVN-001 program. While highly dilutive for existing shareholders (over 20% potential dilution), the successful and upsized financing is a strong signal of the company's ability to secure funding for its critical drug development pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELVN was trading at $45.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $14.79 to $48.53. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.